Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies

Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology …

Email Sign Up. Receive the latest news, events and updates! Sign Up Now

2024年3月11日 · Actinium Pharmaceuticals, Inc. has maintained supply agreements with the DOE since 2009. The DOE has stated that it is exploring the generation of new thorium cows and …

NEW YORK, April 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, …

Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology …

Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies The Pivotal Phase 3 SIERRA Trial for Iomab-B is 100% Enrolled.

2023年3月16日 · Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level …

Iomab-B: Positive Phase 3 SIERRA Trial Seeking U.S. Partner. Iomab-B is a first-in-class targeted radiotherapy intended to improve patient access to potentially curative BMT by simultaneously …

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARC’s or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the …